TD Cowen Reiterates Buy Rating on Arrowhead Pharma (ARWR)

TD Cowen analyst Brendan Smith reiterated a Buy rating on Arrowhead Pharma (NASDAQ: ARWR).

The analyst commented, "ARWR's R&D Day highlighted innovative obesity drugs separately targeting ligand + receptor in the Activin E/ALK7R pathway that regulates lipolysis. CTAs w/ liver targeting ARO-INHBE + adipocyte-targeting ARO-ALK7 by YE:24 offer dual-tracked approach to sizable commercial market. Well-designed Ph1/2 studies with terz combo cohorts should maximize utility of early data + expedite path to market."

For an analyst ratings summary and ratings history on Arrowhead Pharma click here. For more ratings news on Arrowhead Pharma click here.

Shares of Arrowhead Pharma closed at $23.60 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Datavault AI (DVLT) Will Acquire CyberCatch in an All-Cash Transaction